VanEck Biotech ETF (BBH)
| Assets | $339.38M |
| Expense Ratio | 0.35% |
| PE Ratio | 20.45 |
| Shares Out | 2.16M |
| Dividend (ttm) | $1.25 |
| Dividend Yield | 0.80% |
| Ex-Dividend Date | Dec 23, 2024 |
| Payout Frequency | Annual |
| Payout Ratio | 16.23% |
| Volume | 3,747 |
| Open | 155.70 |
| Previous Close | 155.68 |
| Day's Range | 155.70 - 158.47 |
| 52-Week Low | 135.34 |
| 52-Week High | 183.65 |
| Beta | 0.73 |
| Holdings | 25 |
| Inception Date | Dec 20, 2011 |
About BBH
Fund Home PageThe VanEck Biotech ETF (BBH) is an exchange-traded fund that is based on the MVIS US Listed Biotech 25 index, a market-cap-weighted index of the 25 largest biotech firms globally. BBH was launched on Dec 20, 2011 and is issued by VanEck.
Top 10 Holdings
70.67% of assets| Name | Symbol | Weight |
|---|---|---|
| Amgen Inc. | AMGN | 16.38% |
| Gilead Sciences, Inc. | GILD | 13.08% |
| Vertex Pharmaceuticals Incorporated | VRTX | 10.63% |
| Regeneron Pharmaceuticals, Inc. | REGN | 5.18% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 4.91% |
| argenx SE | ARGX | 4.64% |
| IQVIA Holdings Inc. | IQV | 4.57% |
| Natera, Inc. | NTRA | 4.29% |
| Biogen Inc. | BIIB | 3.54% |
| Insmed Incorporated | INSM | 3.44% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 23, 2024 | $1.2517 | Dec 24, 2024 |
| Dec 18, 2023 | $0.7127 | Dec 22, 2023 |
| Dec 19, 2022 | $0.7488 | Dec 23, 2022 |
| Dec 20, 2021 | $0.3972 | Dec 27, 2021 |
| Dec 21, 2020 | $0.6079 | Dec 28, 2020 |
| Dec 23, 2019 | $0.4724 | Dec 30, 2019 |
Performance
BBH had a total return of -5.69% in the past year, including dividends. Since the fund's inception, the average annual return has been 12.19%.
News
BBH: Fear Of Price Controls Is Not The Problem
The executive order aims to reduce drug prices by allowing direct sales to consumers and cutting out PBMs but faces significant challenges. The main risk for biotech is FDA approval delays due to skep...
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...
BBH: Buy Rating, As Tech Investors Look Beyond FAANG
Biotechnology sector experiencing exponential growth driven by emerging technologies addressing global challenges. VanEck Biotech ETF tracks top U.S.-listed biotech companies, offers exposure to innov...
ETF Investors Indicate Active Strategies and Product Innovation Will Fuel the Industry's Continued Growth: BBH 2024 Global ETF Investor Survey
BOSTON--(BUSINESS WIRE)--As the ETF industry reaches a milestone of $12.71 trillion in global assets, the Brown Brothers Harriman 2024 Global ETF Investor Survey finds that investors plan to further i...
Why Biotech Stocks May Be Ready For A Recovery
Jared Ablass, Vice President, Portfolio Research at TD Asset Management, speaks with Greg Bonnell about how the biotech sector could benefit once rates start to come down. Why beaten down Biotech stoc...
BBH: A Solid Way To Play A Comeback In Biotech
Biotech sector has potential for outperformance in the next year. VanEck Biotech ETF is a good product to consider for exposure to the sector. BBH focuses on large-cap biotech stocks, offering a more ...
BBH: Our Favorite Biotech ETF Can Keep Outperforming
VanEck Biotech ETF has outperformed alternative industry ETFs in recent years through its concentration in large-cap leaders. Biotech companies are benefiting from new artificial intelligence tools se...
BBH: A Solid Choice For Biotech Exposure
There are several choices for investors interested in biotech exposure through an ETF. Data analysis shows that biotech ETF returns are more sensitive to timing than the S&P500 and have higher probabi...
Brown Brothers Harriman Private Banking Team Expands in Philadelphia
PHILADELPHIA--(BUSINESS WIRE)--The Private Banking arm of Brown Brothers Harriman & Co. (BBH) is pleased to announce the expansion and strengthening of its Corporate Advisory and Banking team in Phi...
BBH: Portfolio Of Large-Cap Biotechnology Stocks Has Delivered Strong Returns
The BBH ETF has an asset base of $520 million, posted strong growth over the past 6 months, and is trading much higher than its pre-pandemic period price range. BMRN, ARGX, ALNY, BIIB, BGNE, GILD, MRN...
Why Now Could Be The Time To Consider Neuroscience Investments
Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomic...
What The Inflation Reduction Act Means For Drug Prices
The recently enacted Inflation Reduction Act looks to rein in prescription drug prices and could impact the pharma industry's long-term financial performance. The legislation caps out-of-pocket costs ...
BBH ETF: Buy This ETF At Discounted Price And Hold It For Long Term
BBH's price multiples indicate an undervaluation and its major holdings have started recording significant price growth. BBH has strong fundamentals and has performed well enough in the medium and lon...
XBI And IBB: Sell Technology And Buy Biotech, The Only Undervalued Non-Cyclical Growth Sector
The macroeconomic backdrop of Fed interest rate hikes is rapidly deflating overvalued technology companies and "crypto-collectibles." We expect the technology sector to underperform value and biotech.
BBH: Better Than IBB For Covid Exposure Including The Omicron Variant
The relatively less known VanEck's BBH has delivered a better one-year performance than the popular iShares' IBB.
BBH: This ETF Provides Robust Returns To Investors In The Biotech Sector
VanEck Vectors Biotech ETF is a biotech centric ETF with passive investment approach. The fund invests in a small number of biotech companies.
